AbbVie hep C combo fast-tracked in U.S. and EU; Merck's Gardasil wins new indication in Europe;

> AbbVie's ($ABBV) all-oral hep C combo has won expedited assessment in both the U.S. and the EU. Report | Article

> Europe has approved Merck's ($MRK) Gardasil vaccine to prevent anal cancer. Report

> Bristol-Myers Squibb's ($BMY) "The Pink Drive" campaign took bronze at the Goafest's Abby awards. Story

> Takeda and Affymax ($AFFY) have terminated their collaboration and license agreement on anemia drug Omontys and will withdraw their NDA. More (sub. req.)

> Roche's ($RHHBY) Gazyvaro has won Swiss approval for the therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Release

> U.K. cost watchdog NICE has given its recommendation to Sucampo Pharmaceuticals' constipation med, Amitiza. Release

> Boehringer Ingelheim has earned The Information Standard certification, commissioned by England's National Health Service, for the quality of its healthcare information. Report

And Finally... U.S. submission stumbled at the Lions Health Festival. More

Suggested Articles

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Merck CEO Ken Frazier, during a Forbes panel, called on private industry to "stabilize society" amid growing economic inequity and racial injustice.

Pharma TV advertising spiked to hit $182 million in September, even without the usually ubiquitous fall football media to play it on.